View in EDS

1143PResponses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX).

Saved in:
Bibliographic Details
Title: 1143PResponses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX).
Authors: Hecht, J R1 (AUTHOR), Naing, A2 (AUTHOR), Falchook, G S3 (AUTHOR), Patel, M R4 (AUTHOR), Aljumaily, R5 (AUTHOR), Wong, D J6 (AUTHOR), Autio, K A7 (AUTHOR), Wainberg, Z A6 (AUTHOR), Javle, M8 (AUTHOR), Bendell, J9 (AUTHOR)
Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p. 1 Chart.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdy288.016